Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors.

ABSTRACT:

Introduction

Despite SARS-CoV-2 pandemic has subsided, vaccine response profiling in patients with cancer remains critical.

Methods

We longitudinally assessed humoral and cellular immunity in adults with solid tumours treated with chemotherapy (ChT) or non-ChT regimens after two mRNA vaccine doses plus booster, compared with vaccinated cancer-free controls, naturally infected (convalescent) subjects including both patients with cancer and cancer-free individuals, and unvaccinated/uninfected individuals with or without cancer as a baseline reference.

Results

Anti-Spike IgG titres matched cancer-free controls, but anti-RBD titres and neutralising activity were consistently lower in cancer post-vaccination, most markedly with ChT, and declined faster over 4-6 months. Boo

SUBMITTER: Favalli A 

PROVIDER: S-EPMC12507793 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature